Abeona Therapeutics Inc (ABEO.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|61||2015||Executive Chairman of the Board|
|2018||President, Chief Scientific Officer|
|55||2018||Chief Executive Officer, Director|
|54||2017||Chief Operating Officer|
|64||2016||Senior Vice President - Research and Development|
- BRIEF-Abeona Therapeutics Provides Clinical Update On MPS IIIA Gene Therapy Trial
- BRIEF-Abeona Therapeutics Posts Q1 Loss Of $0.18 Per Share
- BRIEF-Abeona Announces FDA Grants Rmat Designation To ABO-102 Gene Therapy In MPS Iiia
- BRIEF-Abeona Therapeutics Receives Orphan Drug Designation In The European Union For ABO-202 Gene Therapy Program In Batten Disease
- BRIEF-Abeona Therapeutics Appoints Carsten Thiel, Ph.D., As Chief Executive Officer